Genetic Investigations in Spontaneous Coronary Artery Dissection (SCAD)
The purpose of the research is to identify mutations (defects in the genetic blueprint) that cause spontaneous coronary artery dissection (SCAD), in other words, spontaneous tears in blood vessels that supply the heart.
Some mutations may be inherited (passed on) from a parent without an apparent blood vessel problem while others may develop for the first time in the affected person.
Spontaneous Coronary Artery Dissection
|Study Design:||Observational Model: Family-Based|
|Official Title:||Genetic Investigations in Spontaneous Coronary Artery Dissection (SCAD)|
- Identification of one or more gene mutation responsible for SCAD [ Time Frame: By end of study ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||May 2011|
|Estimated Study Completion Date:||December 2020|
|Estimated Primary Completion Date:||December 2017 (Final data collection date for primary outcome measure)|
Study question: Do mutations within certain genes cause or confer susceptibility to spontaneous coronary artery dissection (SCAD)?
- Create a genomic DNA and plasma biobank for individuals diagnosed with SCAD.
- Identify inherited and de novo/new mutations that underlie SCAD.
Long term objective:Discover molecular and cellular mechanisms of SCAD and develop biomarkers to enable prediction and prevention.
The purpose of the research is to identify mutations (defects in the genetic blueprint) that cause tears in blood vessels that supply the heart. Some mutations may be inherited (passed on) from a parent without an apparent blood vessel problem while others may develop for the first time in the affected person. The study includes individuals diagnosed with spontaneous coronary artery dissection and their biological parents.
Adults with SCAD will be identified both retrospectively and prospectively.Confirmation of the diagnosis by review of coronary angiography will be required before proceeding with the informed consent process and blood or saliva sample procurement.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01427179
|Contact: Jill Boyum||507-266-3180||MayoSCAD@Mayo.edu|
|Contact: Matt Hoplinemail@example.com|
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Contact: Jill Boyum 507-266-3180 firstname.lastname@example.org|
|Contact: Matt Hoplin, M.S. 507-284-9482 email@example.com|
|Principal Investigator: Timothy M. Olson, M.D.|
|Principal Investigator: Sharonne N. Hayes, M.D.|
|Principal Investigator:||Timothy M. Olson, M.D.||Mayo Clinic|
|Principal Investigator:||Sharonne N. Hayes, M.D.||Mayo Clinic|